Floatz logo

Therapeutic Asset Ratings

3,272 results matching 1 filter

91,564 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Pertuzumab
Gastric Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pertuzumab
Head And Neck Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pertuzumab
Hematopoietic And Lymphoid Cell Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Pertuzumab
Renal Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pertuzumab
Hepatocellular Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pertuzumab
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pertuzumab
Uterine Corpus Cancer
National Cancer Institute (NCI)P2CCC (53)
Pertuzumab
Uterine Cancer
National Cancer Institute (NCI)P2CCC (53)
Pertuzumab
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pertuzumab
Thyroid Gland Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pevonedistat
Cholangiocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Pevonedistat
Hepatocellular Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pevonedistat
Lung Cancer
National Cancer Institute (NCI)P2CCC (53)
Pevonedistat
Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)P2CCC (53)
PI3K/MTOR INHIBITOR LY3023414
Histiocytic Sarcoma
National Cancer Institute (NCI)P2CCC (53)
PI3K/MTOR INHIBITOR LY3023414
Juvenile Xanthogranuloma
National Cancer Institute (NCI)P2CCC (53)
Pneumococcal Polyvalent Vaccine
Pregerminal Center Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Pomalidomide
Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
National Cancer Institute (NCI)P2CCC (53)
Pomalidomide
Acute Myeloid Leukemia With Multilineage Dysplasia
National Cancer Institute (NCI)P2CCC (53)
Ponatinib
B-Cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)P2CCC (53)
Relatlimab
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Relatlimab
Breast Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Relatlimab
Cervical Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Relatlimab
Endometrial Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Relatlimab
Carcinoma Of Esophagus
National Cancer Institute (NCI)P2CCC (53)
Showing 1951 to 1975 of 3,272 assets
PreviousPage 79 of 131Next